A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
for Bladder Cancer
10 locations incl. Los Angeles
Sponsor: EvolveImmune United, Inc
Sex: All·Age: 18+
Code: NCT07217171·Phase 1·Recruiting